Rosetta Genomics Ltd (ROSG) 3.65 $ROSG
Rosetta Genomics Receives First Patent Allowance in Japan
Business Wire - Tue Feb 10, 7:41AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company received a Notice of Allowance from the Japan Patent Office (JPO) for Japanese Patent Application No. 2007-512601, which relates to human miR-92b. The composition of matter patent to be issued claims the sequence of miR-92b and its complement, as well as its use as a probe, including in biochips. miR-92b has been shown to be elevated in cancer and is a key element of the Company's lead oncology diagnostic, the Rosetta Cancer Origin Test(TM) (COT).
ROSG: 3.65 (+0.32)
Rosetta Genomics Announces Commercial Partnership with Precipio Diagnostics
Business Wire - Mon Feb 09, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has entered into a co-promotional commercial partnership with Precipio Diagnostics ("Precipio"
for the sales and marketing of Precipio's oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia and Washington, D.C., with an expectation to expand nationally over time.
ROSG: 3.65 (+0.32)
Clinician Survey Supporting Value Proposition of the Rosetta Kidney Cancer Test(TM) Published in the Journal of Kidney Cancer
Business Wire - Tue Jan 20, 7:01AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of an article in the Journal of Kidney Cancer in support of the use of the Rosetta Kidney Cancer Test(TM). Titled "Clinicians' Real World Perceptions of Pre-Nephrectomy Diagnostic Biopsy Performance as a Driver of Reduction in Unnecessary Surgeries in Renal Tumors," the article appeared in the online edition on January 18, 2015 and can be accessed here.
ROSG: 3.65 (+0.32)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Rosetta Genomics Issues Letter to Shareholders
Business Wire - Mon Jan 12, 7:01AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the posting of the following Letter to Shareholders from President and Chief Executive Officer Kenneth A. Berlin to the Investors section of the Company's website at www.rosettagenomics.com.
ROSG: 3.65 (+0.32)
Rosetta Genomics Announces Launch of Admera Health's Sequencing-Based Oncology Tests
Business Wire - Thu Jan 08, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the commercial launch of the first of the oncology testing services gained through its previously announced collaboration with Admera Health (October 30, 2014). Rosetta Genomics is now offering PGxOne(TM), a pharmacogenomics test that predicts patients' responses to drugs based on their personal genetic makeup to avoid adverse effects; and EGFR and KRAS clinical sequencing, which provides genomic analysis of those tumor-based mutations from patient tissue to provide clinically relevant information relating to potential response to therapy, which is helpful for physicians, pathologists and researchers.
ROSG: 3.65 (+0.32)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 3.65 (+0.32), ISIS: 63.86 (-0.43), DRNA: 21.30 (-0.06), ALNY: 95.54 (+1.67), ARWR: 6.77 (+0.21), SRPT: 12.76 (+0.11), ALXN: 182.29 (+6.02), TKMR: 21.45 (-0.22), RGLS: 16.85 (-0.13)
Rosetta Genomics to Present at LD MICRO "Main Event" Micro-Cap Growth Conference on December 3, 2014
Business Wire - Tue Nov 25, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Kenneth A. Berlin, President and CEO of Rosetta Genomics, will present a corporate overview on Wednesday, December 3, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
ROSG: 3.65 (+0.32)
Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST
ROSG: 3.65 (+0.32), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
Marketwired - Wed Nov 19, 3:10PM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD).
ROSG: 3.65 (+0.32)
Rosetta Genomics Announces Publication of Data Demonstrating Differentiation of Adrenocortical Carcinomas from Adenomas by microRNA Profiling
Business Wire - Tue Nov 04, 7:38AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of data relating to the Company's microRNA platform in the online edition of peer-reviewed journal, "Applied Immunohistochemistry and Molecular Morphology." The article entitled, "Specific MicroRNAs Differentiate Adrenocortical Adenomas from Carcinomas and Correlate with Weiss Histopathologic System," highlights the ability of microRNA profiles to differentiate adrenocortical carcinomas from adenomas with very good correlation with the histologic Weiss system for identifying malignancy in adrenocortical tumors (ACTs). This study is part of a collaborative project between Rosetta Genomics and Prof. Meora Feinmesser, M.D., Head of the Institute of Pathology at the Rabin Medical Center in Israel.
ROSG: 3.65 (+0.32)
Rosetta Genomics Partners with Admera Health for the Commercialization of Current and Future Sequencing-Based Oncology Tests
Business Wire - Thu Oct 30, 7:02AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces a collaboration with Admera Health, a spin-off from the clinical services unit of GENEWIZ, Inc., a leading global genomics company. Focused on personalized medicine, Admera Health is a molecular diagnostics company that aims to develop and deliver cost-effective tests that fulfill unmet medical needs, including clinical molecular oncology diagnostics.
ROSG: 3.65 (+0.32)
Rosetta Genomics' microRNA-based assay for Thyroid Cancer Highlighted in Poster Presentation at 84th Annual Meeting of the American Thyroid Association
Business Wire - Thu Oct 23, 7:02AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that data in support of the Company's microRNA-based assay for indeterminate thyroid nodules will be highlighted in a poster presentation entitled, "MicroRNAs as a powerful diagnostic tool for thyroid nodule classification in pre-operative samples," at the upcoming 84th Annual Meeting of the American Thyroid Association (ATA) taking place from October 29th through November 2nd at the Hotel Del Coronado in Coronado, Calif.
ROSG: 3.65 (+0.32)
Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic
Marketwired - Tue Oct 21, 7:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the initiation by the European Infrastructure for Translational Medicine (EATRIS), of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool.
ROSG: 3.65 (+0.32)
Prosensa begins FDA submission process for DMD drug candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 2:37PM CDT
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
GlobeNewswire - Mon Oct 13, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leading molecular diagnostics company advancing microRNA-based diagnostics based on its proprietary microRNA platform technologies, today announced a collaboration that will combine both companies' platform technologies in an innovative approach to cancer diagnostics. The collaboration will utilize Biocept's patented microfluidic channel technology to capture CTCs and then apply Rosetta Genomics' technical expertise and proprietary methods to extract and analyze microRNA from these cells. The companies will test for markers currently offered by Rosetta as well as pursue new potential markers.
ROSG: 3.65 (+0.32), BIOC: 1.41 (+0.22)
Rosetta Genomics Receives First Patent Allowance in Japan
Business Wire - Tue Feb 10, 7:41AM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company received a Notice of Allowance from the Japan Patent Office (JPO) for Japanese Patent Application No. 2007-512601, which relates to human miR-92b. The composition of matter patent to be issued claims the sequence of miR-92b and its complement, as well as its use as a probe, including in biochips. miR-92b has been shown to be elevated in cancer and is a key element of the Company's lead oncology diagnostic, the Rosetta Cancer Origin Test(TM) (COT).
ROSG: 3.65 (+0.32)
Rosetta Genomics Announces Commercial Partnership with Precipio Diagnostics
Business Wire - Mon Feb 09, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has entered into a co-promotional commercial partnership with Precipio Diagnostics ("Precipio"
for the sales and marketing of Precipio's oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia and Washington, D.C., with an expectation to expand nationally over time. ROSG: 3.65 (+0.32)
Clinician Survey Supporting Value Proposition of the Rosetta Kidney Cancer Test(TM) Published in the Journal of Kidney Cancer
Business Wire - Tue Jan 20, 7:01AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of an article in the Journal of Kidney Cancer in support of the use of the Rosetta Kidney Cancer Test(TM). Titled "Clinicians' Real World Perceptions of Pre-Nephrectomy Diagnostic Biopsy Performance as a Driver of Reduction in Unnecessary Surgeries in Renal Tumors," the article appeared in the online edition on January 18, 2015 and can be accessed here.
ROSG: 3.65 (+0.32)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Rosetta Genomics Issues Letter to Shareholders
Business Wire - Mon Jan 12, 7:01AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the posting of the following Letter to Shareholders from President and Chief Executive Officer Kenneth A. Berlin to the Investors section of the Company's website at www.rosettagenomics.com.
ROSG: 3.65 (+0.32)
Rosetta Genomics Announces Launch of Admera Health's Sequencing-Based Oncology Tests
Business Wire - Thu Jan 08, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the commercial launch of the first of the oncology testing services gained through its previously announced collaboration with Admera Health (October 30, 2014). Rosetta Genomics is now offering PGxOne(TM), a pharmacogenomics test that predicts patients' responses to drugs based on their personal genetic makeup to avoid adverse effects; and EGFR and KRAS clinical sequencing, which provides genomic analysis of those tumor-based mutations from patient tissue to provide clinically relevant information relating to potential response to therapy, which is helpful for physicians, pathologists and researchers.
ROSG: 3.65 (+0.32)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 3.65 (+0.32), ISIS: 63.86 (-0.43), DRNA: 21.30 (-0.06), ALNY: 95.54 (+1.67), ARWR: 6.77 (+0.21), SRPT: 12.76 (+0.11), ALXN: 182.29 (+6.02), TKMR: 21.45 (-0.22), RGLS: 16.85 (-0.13)
Rosetta Genomics to Present at LD MICRO "Main Event" Micro-Cap Growth Conference on December 3, 2014
Business Wire - Tue Nov 25, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Kenneth A. Berlin, President and CEO of Rosetta Genomics, will present a corporate overview on Wednesday, December 3, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
ROSG: 3.65 (+0.32)
Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST
ROSG: 3.65 (+0.32), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
Marketwired - Wed Nov 19, 3:10PM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD).
ROSG: 3.65 (+0.32)
Rosetta Genomics Announces Publication of Data Demonstrating Differentiation of Adrenocortical Carcinomas from Adenomas by microRNA Profiling
Business Wire - Tue Nov 04, 7:38AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of data relating to the Company's microRNA platform in the online edition of peer-reviewed journal, "Applied Immunohistochemistry and Molecular Morphology." The article entitled, "Specific MicroRNAs Differentiate Adrenocortical Adenomas from Carcinomas and Correlate with Weiss Histopathologic System," highlights the ability of microRNA profiles to differentiate adrenocortical carcinomas from adenomas with very good correlation with the histologic Weiss system for identifying malignancy in adrenocortical tumors (ACTs). This study is part of a collaborative project between Rosetta Genomics and Prof. Meora Feinmesser, M.D., Head of the Institute of Pathology at the Rabin Medical Center in Israel.
ROSG: 3.65 (+0.32)
Rosetta Genomics Partners with Admera Health for the Commercialization of Current and Future Sequencing-Based Oncology Tests
Business Wire - Thu Oct 30, 7:02AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces a collaboration with Admera Health, a spin-off from the clinical services unit of GENEWIZ, Inc., a leading global genomics company. Focused on personalized medicine, Admera Health is a molecular diagnostics company that aims to develop and deliver cost-effective tests that fulfill unmet medical needs, including clinical molecular oncology diagnostics.
ROSG: 3.65 (+0.32)
Rosetta Genomics' microRNA-based assay for Thyroid Cancer Highlighted in Poster Presentation at 84th Annual Meeting of the American Thyroid Association
Business Wire - Thu Oct 23, 7:02AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that data in support of the Company's microRNA-based assay for indeterminate thyroid nodules will be highlighted in a poster presentation entitled, "MicroRNAs as a powerful diagnostic tool for thyroid nodule classification in pre-operative samples," at the upcoming 84th Annual Meeting of the American Thyroid Association (ATA) taking place from October 29th through November 2nd at the Hotel Del Coronado in Coronado, Calif.
ROSG: 3.65 (+0.32)
Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic
Marketwired - Tue Oct 21, 7:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the initiation by the European Infrastructure for Translational Medicine (EATRIS), of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool.
ROSG: 3.65 (+0.32)
Prosensa begins FDA submission process for DMD drug candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 2:37PM CDT
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
GlobeNewswire - Mon Oct 13, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leading molecular diagnostics company advancing microRNA-based diagnostics based on its proprietary microRNA platform technologies, today announced a collaboration that will combine both companies' platform technologies in an innovative approach to cancer diagnostics. The collaboration will utilize Biocept's patented microfluidic channel technology to capture CTCs and then apply Rosetta Genomics' technical expertise and proprietary methods to extract and analyze microRNA from these cells. The companies will test for markers currently offered by Rosetta as well as pursue new potential markers.
ROSG: 3.65 (+0.32), BIOC: 1.41 (+0.22)
